Cargando…

Synergy of Iron Chelators and Therapeutic Peptide Sequences Delivered via a Magnetic Nanocarrier

Here, we report the synthesis, characterization, and efficacy study of Fe/Fe(3)O(4)-nanoparticles that were co-labeled with a tumor-homing and membrane-disrupting oligopeptide and the iron-chelator Dp44mT, which belongs to the group of the thiosemicarbazones. Dp44mT and the peptide sequence PLFAERL(...

Descripción completa

Detalles Bibliográficos
Autores principales: Abayaweera, Gayani S., Wang, Hongwang, Shrestha, Tej B., Yu, Jing, Angle, Kyle, Thapa, Prem, Malalasekera, Aruni P., Maurmann, Leila, Troyer, Deryl L., Bossmann, Stefan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618274/
https://www.ncbi.nlm.nih.gov/pubmed/28672849
http://dx.doi.org/10.3390/jfb8030023
Descripción
Sumario:Here, we report the synthesis, characterization, and efficacy study of Fe/Fe(3)O(4)-nanoparticles that were co-labeled with a tumor-homing and membrane-disrupting oligopeptide and the iron-chelator Dp44mT, which belongs to the group of the thiosemicarbazones. Dp44mT and the peptide sequence PLFAERL((D)[KLAKLAKKLAKLAK])CGKRK were tethered to the surface of Fe/Fe(3)O(4) core/shell nanoparticles by utilizing dopamine-anchors. The 26-mer contains two important sequences, which are the tumor targeting peptide CGKRK, and (D)[KLAKLAK](2), known to disrupt the mitochondrial cell walls and to initiate programmed cell death (apoptosis). It is noteworthy that Fe/Fe(3)O(4) nanoparticles can also be used for MRI imaging purposes in live mammals. In a first step of this endeavor, the efficacy of this nanoplatform has been tested on the highly metastatic 4T1 breast cancer cell line. At the optimal ratio of PLFAER(D)[KLAKLAK](2)CGKRK to Dp44mT of 1 to 3.2 at the surface of the dopamine-coated Fe/Fe(3)O(4)-nanocarrier, the IC(50) value after 24 h of incubation was found to be 2.2 times lower for murine breast cancer cells (4T1) than for a murine fibroblast cell line used as control. Based on these encouraging results, the reported approach has the potential of leading to a new generation of nanoplatforms for cancer treatment with considerably enhanced selectivity towards tumor cells.